Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients

Circulation

Volumn 101, Issue 24, 2000, Pages 2829-2832

  Bostom, Andrew G ^a,b,c   Shemin, Douglas ^b   Bagley, Pamela ^c   Massy, Ziad A ^d   Zanabli, Abdul ^b   Christopher, Kenneth ^b   Spiegel, Paul ^b   Jacques, Paul F ^c   Dworkin, Lance ^b   Selhub, Jacob ^c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c TUFTS UNIVERSITY   (United States)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Homocysteine; Kidney; Trials

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; CYANOCOBALAMIN; EPROVA; FOLIC ACID; PYRIDOXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0034691317     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.24.2829     Document Type: Article

References (28)

1. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
2. Bostom AG, Culleton B, Hyperhomocysteinemia in chronic renal disease: disease of the month review. J Am Soc Nephrol. 1999;10:891-900.
3. Bostom AG, Shemin D, Lapane KL, et al. High-dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996;49: 147-152.
4. Perna AF, Ingrosso D, De Santo NG, et al. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol. 1997;8:1899-1905.
5. Touam M, Zingraff J, Jungers P, et al. Effective correction of hyperhomocysteinemia in hemodialysis patients by folinic acid and pyridoxine therapy. Kidney Int. 1999;56:2292-2296.
6. Bayes B, Bonal J, Pastor C, et al. Lipid peroxidation in hemodialysis: preventive role of vitamin E and folinic acid. J Am Soc Nephrol. 1999; 10:274A. Abstract.
7. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
8. Home DW, Patterson D. Lactobacillus casei assay of folic acid derivatives in 96-well microtiter plates. Clin Chem. 1988;34:2357-2359.
9. Shin-Buering Y, Rasshofer R, Endres WA. A new enzymatic method for pyridoxal 5′-phosphate determination. J Inherit Metab Dis. 1981;4: 123-124.
10. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A. 1998;95: 13217-13220.
11. Dallai GE. PC-Size: a program for sample size determinations. Version 2.13. Andover, Mass: 1986.
12. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
13. Bostom AG, Shemin D, Lapane KL, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis. 1996;123:193-202.
14. Schmitz JC, Stuart RK, Priest DG. Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther. 1994; 55:501-508.
15. Campbell DT, Stanley JC. Experimental and quasi-experimental designs for research. Houghton Mifflin College, 1966.
16. Said HM, Vaziri ND, Kariger RK, et al. Intestinal absorption of 5-methyltetrahydrofolate in experimental uremia. Acta Vitaminol Enzymol. 1984;6:339-346.
17. Relief FP, Heyns AP, Oosthuizen M, et al. Aspects of folate metabolism in renal failure. Br J Hematol. 1977;36:405-415.
18. Jennrette JC, Goldman ID, Inhibition of the membrane transport of folates by anions retained in uremia. J Clin Lab Med. 1975;86:834-843.
19. Livant EJ, Tamura T, Johnston KE, et al. Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem. 1994;5:504-508.
20. Massy ZA. Reversal of hyperhomocysteinemia in chronic renal failure: is folic or folinic acid the answer? Nephrol Dial Transplant. 1999;14: 2810-2812.
21. Bostom AG, Brosnan JT, Hall B, et al. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis. 1995;116:59-62.
22. House JD, Brosnan ME, Brosnan JT. Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia. Kidney Int. 1998;54:1601-1607.
23. van Guldener C, Donker AJM, Jakobs C, et al. No net renal extraction of homocysteine in fasting humans. Kidney Int. 1998;54:166-169.
24. van Guldener C, Kulik W, Berger R, et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int. 1999;56: 1064-1071.
25. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients: a randomized, placebo-controlled trial. Ann Intern Med. 1997;127:1089-1092.
26. Beaulieu AJ, Gohh RY, Han H, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999;19:2918-2921.
27. Bostom AG, Shemin D, Gohh RY, et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation. In press.
28. Bostom AG. Homocysteine: "expensive creatinine," or important modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol. 2000;11:149-151.